NESS ZIONA, Israel, Feb. 06, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq:KMDA) (TASE:KMDA.TA), a plasma-derived protein therapeutics company focused on orphan indications, announced today financial results for the three and twelve months ended December 31, 2016.
“We are very pleased with our accomplishments in 2016,” said Amir London, Chief Executive Officer. “We met our revenue guidance for full year 2016, with over 30% growth in our Proprietary Products revenues compared with the previous year, and look forward to a higher rate of revenue growth in this segment in 2017. Moreover, the extension of our supply agreement with Shire for GLASSIA® through 2020 underscores Shire’s solid outlook for higher long-term demand for GLASSIA® in the U.S. This minimum revenue commitment by Shire - $237 million over four years - further strengthens our confidence in achieving our guidance of $100 million in total revenues in 2017 and represents further growth in the following years.”
